Clinical trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
NCT05611671 is registered in ClinicalTrials.gov with Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 21, 2022
- Completion date
- August 31, 2026
- Enrollment
- 280 (actual)
- Sites
- 102
Conditions
As the registry lists them; a condition with its own page is linked.